BAXS finally has a board!Some points:1.BAXS is getting reserach coverage - a good start. The stock will be more visible. However the firms covering BAXS are the underwriters of the IPO, so they will naturally be very bullish about the company. BTW the expected price target after IPO was $8-10. BAXS failed to take off, IMO, because its core business needs a lot of technical background to be fully appreciated.BAXS might be a bit of an acquired taste.Once ivestors will understand that BAXS is the market leader for instruments that play a crucial part in the fields of drug discovery and material sciences, investor interest will grow and BAXS will bloom.2. Structural ProteomicsAfter the Human Genome Project completed the sequencing of all human genes, the focus shifted to the proteins coded by these genes.Genes can be thought as a set of instructions to build proteins. They determine, directly or indirectly, how much of a protein will be built, when it will be built, and what its shape will be.Proteins are the real machinery of life, and how they function is in large part determined by their shape and their "structural" properties. Knowledge of the shape of proteins, their three-dimensional structure, can explain their role in health and disease.So now the Human Genome project is evolving into the next stage: Structural Genomics.However, Discovering the shape of all human proteins is a task orders of magnitude more complex than sequencing all of human DNA. Nonetheless, hundreds of millions of dollars are being invested in this project, both by governemnt and industry, in the hope that the windfall will be a treasure trove of tools to design better drugs (or new drugs altogether).The main experimental technique used to determine the structure of proteins is X-ray crystallography, in which a beam of X-rays is shot at a protein crystal, and the pattern generated by the interaction of the atoms of the protein with the beam is analyzed to deduce their position in space, which defines the shape of the protein (along with lots of other chemical/physical info).BAXS is undoubtedly the market leader for X-ray diffraction equipment, and if R&D expenditure for protein structure determination will continue growing, BAXS will grow accordingly.I hope this info was useful. Thanks for your patience.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat